TY - JOUR
T1 - Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas
T2 - north american brain tumor consortium study 04-03
AU - Lee, Eudocia Q.
AU - Puduvalli, Vinay K.
AU - Reid, Joel M.
AU - Kuhn, John G.
AU - Lamborn, Kathleen R.
AU - Cloughesy, Timothy F.
AU - Chang, Susan M.
AU - Drappatz, Jan
AU - Yung, W. K.Alfred
AU - Gilbert, Mark R.
AU - Robins, H. Ian
AU - Lieberman, Frank S.
AU - Lassman, Andrew B.
AU - McGovern, Renee M.
AU - Xu, Jihong
AU - Desideri, Serena
AU - Ye, Xiabu
AU - Ames, Matthew M.
AU - Espinoza-Delgado, Igor
AU - Prados, Michael D.
AU - Wen, Patrick Y.
PY - 2012/11/1
Y1 - 2012/11/1
N2 - Purpose: A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG). Experimental Design: This phase I, dose-finding, investigational study was conducted in two parts. Part 1 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m2/day for 5 days every 28 days. Part 2 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m 2/day for 5 days of the first cycle and 200 mg/m2/day for 5 days of the subsequent 28-day cycles. Results: In part 1, the MTD of vorinostat administered on days 1 to 7 and 15 to 21 of every 28-day cycle, in combination with TMZ, was 500 mg daily. Dose-limiting toxicities (DLT) included grade 3 anorexia, grade 3 ALT, and grade 5 hemorrhage in the setting of grade 4 thrombocytopenia. In part 2, the MTD of vorinostat on days 1 to 7 and 15 to 21 of every 28-day cycle, combined with TMZ, was 400 mg daily. No DLTs were encountered, but vorinostat dosing could not be escalated further due to thrombocytopenia. The most common serious adverse events were fatigue, lymphopenia, thrombocytopenia, and thromboembolic events. There were no apparent pharmacokinetic interactions between vorinostat and TMZ. Vorinostat treatment resulted in hyperacetylation of histones H3 and H4 in peripheral mononuclear cells. Conclusion: Vorinostat in combination with temozolomide is well tolerated in patients with HGG. A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.
AB - Purpose: A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG). Experimental Design: This phase I, dose-finding, investigational study was conducted in two parts. Part 1 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m2/day for 5 days every 28 days. Part 2 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m 2/day for 5 days of the first cycle and 200 mg/m2/day for 5 days of the subsequent 28-day cycles. Results: In part 1, the MTD of vorinostat administered on days 1 to 7 and 15 to 21 of every 28-day cycle, in combination with TMZ, was 500 mg daily. Dose-limiting toxicities (DLT) included grade 3 anorexia, grade 3 ALT, and grade 5 hemorrhage in the setting of grade 4 thrombocytopenia. In part 2, the MTD of vorinostat on days 1 to 7 and 15 to 21 of every 28-day cycle, combined with TMZ, was 400 mg daily. No DLTs were encountered, but vorinostat dosing could not be escalated further due to thrombocytopenia. The most common serious adverse events were fatigue, lymphopenia, thrombocytopenia, and thromboembolic events. There were no apparent pharmacokinetic interactions between vorinostat and TMZ. Vorinostat treatment resulted in hyperacetylation of histones H3 and H4 in peripheral mononuclear cells. Conclusion: Vorinostat in combination with temozolomide is well tolerated in patients with HGG. A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.
UR - http://www.scopus.com/inward/record.url?scp=84868561843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868561843&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-1841
DO - 10.1158/1078-0432.CCR-12-1841
M3 - Article
C2 - 22923449
AN - SCOPUS:84868561843
SN - 1078-0432
VL - 18
SP - 6032
EP - 6039
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 21
ER -